Research advances in calcitonin gene-related peptide monoclonal antibodies and botulinum toxin A for treatment of chronic migraine
- VernacularTitle:A型肉毒毒素与CGRP单克隆抗体药物治疗慢性偏头痛的研究进展
- Author:
Hongru ZHAO
1
Author Information
- Publication Type:Journal Article
- Keywords: Botulinum toxin A; Calcitonin gene-related peptide; Monoclonal antibody; Chronic migraine; Preventive therapy
- From: Journal of Apoplexy and Nervous Diseases 2023;40(12):1063-1068
- CountryChina
- Language:Chinese
- Abstract: Previous studies have shown that botulinum toxin A can significantly reduce headache frequency and intensity and headache-related dysfunction in patients with chronic migraine.Recent evidence has discovered that multiple monoclonal antibodies targeting the calcitonin gene-related peptide （CGRP） pathway can also significantly improve the clinical outcome of chronic migraine.Few studies have compared the preventive effects of the two treatments for chronic migraine.This review focuses on the efficacy and safety of botulinum toxin A and monoclonal antibodies against CGRP and CGRP receptor （CGRPr） in the treatment of chronic migraine，as well as the effectiveness of CGRPr monoclonal antibodies following a poor response to botulinum toxin A，aiming to provide a reference for clinical treatment selection.
- Full text:2024061221070693993Research advances in calcitonin gene-related peptide monoclonal antibodies and botulinum toxin A for treatment of chronic migraine.pdf
